Start Aktuellt Metodbok Resurser Nätverk Artiklar Om NEPI
NEPI - nätverk för läkemedelsepidemiologi

Arkiv ABLA Artiklar 2007- Varningsinformation

Publikationer 1994-2007

1995

  1. Ranstam J. Statistics and mcyedical research. Basic principles review. Acta Orthop Scand 1995;66:193-195.
  2. Merlo J, Lindberg G, Ranstam J, Melander A, Råstam L. Blood pressure and mortality in elderly people. Lancet 1995:345;1434 (letter).

1996

  1. Merlo J, Hedblad B, Ögren M, Ranstam J, Östergren P-O, Ekedahl A, Hanson B S, Isacsson S-O, Melander A. Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics. Eur J Clin Pharmacol 1996;49:261-265.
  2. Merlo J, Råstam L, Ranstam J, Wessling A, Melander A. Out-patient antihypertensive drug utilisation and stroke mortality – An ecologic study. Eur J Publ Health 1996;6:113-117.
  3. Merlo J, Ranstam J, Liedholm H, Hedblad B, Lindberg G, Lindblad U, Isacsson S-O, Melander A, Råstam L. Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs. population based cohort study. Br Med J 1996;313:457-461. 
  4. Merlo J, Wessling A, Melander A. Comparison of dose standard units for drug utilisation studies. Eur J Clin Pharmacol 1996;50:27-30.
  5. Melander A. Review of previous impaired glucose tolerance intervention studies. Diab Med 1996;13: (Suppl 2) 520-522.
  6. Melander A. Intervention trials in impaired glucose tolerance. IDF Bulletin 1996;41:22-24.
  7. Melander A. Oral antidiabetic drugs. An overview. Diab Med 1996;13: (Suppl 6):143-148.
  8. Ranstam J, Merlo J, Blennow G, Hanson BS, Östergren P-O, Melander A. Impaired cognitive function in elderly men exposed to benzodiazepines or other anxiolytics. Eur J Publ Health 1996;6:113-117.
  9. Ranstam J. A common misconception about p values and their consequences. Acta Orthop Scand 1996;67:505-507.
  10. Råstam L, Lindberg G, Folsom AR, Burke GL, Nilsson-Ehle P, Lundblad A. Association between serum sialic acid concentration and carotid atherosclerosis measured by B-mode ultrasound. Int J Epid 1996;25:953-958.
  11. Melander A. Användningen av lugnande medel och sömnmedel i Sverige. NEPI-rapport 1996 (Utilisation of anxiolytics and hypnotics in Sweden).
  12. Westerlund-Muz G, Larsson S, Lilja J, Melander A. Användning av sömnmedel och lugnande medel bland sjukskrivna personer i Stockholm (ISBN 91-972497-8-5). Rapport nr 15 från Försäkrings-kassan i Stockholm, juni 1996. (Utilisation of hypnotics and anxiolytics in patients on sick-leave in Stockholm).
  13. Westerlund-Muz G, Larsson S, Lilja J, Melander A. Friskskrivning och användning av lugnande medel och sömnmedel. (ISBN 91-972946-2-4). Rapport nr 19 från Försäkringskassan i Stockholm, oktober 1998. (Utilisation of anxiolytics and hypnotics in subjects off sick-leave).

1997

  1. Carlsson R, Lindberg G, Westin L, Israelsson B. Influence of coronary nursing management follow up on lifestyle after acute myocardial infarction. Heart 1997;77:356-259.
  2. Lindberg G, Hiroyasu I, Råstam L, Lundblad A, Folsom AR. Serum sialic acid and its correlates in community samples from Akita, Japan and Minneapolis, USA. Int J Epid 1997;26:58-63.
  3. Merlo J, Ranstam J. Ocular safety of anti-ulcer drugs. Br J Clin Pharmacol 1997;43:449.
  4. Rydberg T, Jönsson A, Karlsson MO, Melander A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1997;43:373-381.

  5. Rydberg T. Pharmacokinetics – Effect relations of glibenclamide and its metabolites in humans. Doctoral dissertation, Lund University 1997. Länk till Lund University Dessertation Abstracts
  6. Lebovitz HE, Melander A. Sulfonylureas: Basic aspects and clinical uses. International Textbook of Diabetes Mellitus, Second edition. Eds. KGMM Alberti, P Zimmet, R A DeFronzo and H Keen, John Wiley & Sons Ltd, Chichester, 1997:817-840.
  7. Hermann LS, Melander A. Biguanides: Basic aspects and clinical uses. International International Textbook of Diabetes Mellitus, Second edition. Eds. KGMM Alberti, P Zimmet, R A DeFronzo and H Keen, John Wiley & Sons Ltd, 1997:841-864.
  8. Knowler WC, Sartor G, Melander A, Scherstén B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997;40:680-686.
  9. Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic subjects with normal and with impaired renal function. Diabetologia 1997;40:1252 (meeting abstract).

1998

  1. Melander A, Donnelly R, Rydberg T. Is there a concentration-effect relationship for sulphonylureas? Clin Pharmacokinet 1998;34:181-188.
  2. Lindberg G, Bingefors K, Ranstam J, Råstam L, Melander A. Use of calcium channel blockers is linked to suicide risk - ecological findings confirmed in a population-based cohort study. Br Med J 1998;316:741-745.
  3. Nilsson JLG, Nilsson A, Lundh K. Användningen av generiska läkemedel i Sverige. NEPI-Rapport 1998 ISBN 91-8627-476-7. (Utilisation of generic drugs in Sweden).

  4. Merlo J. Pharmacoepidemiological studies on cardiovascular drugs, with special reference to effectiveness and safety of blood pressure lowering drugs. Doctoral dissertation, Lund University, 1998. Länk till Lund University Dessertation Abstracts
  5. Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998;53:429-435.
  6. Boeg-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A. Råstam L. Risk factor clustering in patients with hypertension and non-insulin-dependent diabetes mellitus. The Skaraborg Hypertension Project. J Int Med 1998; 243: 223-232.
  7. Melander A. Pharmacological intervention: the antidiabetic approach. Eur J Clin Invest 1998;28 (Suppl 2) 23-26.
  8. Hermann LS. Combination therapy with insulin and metformin: Endocrine Practice 1998; 4: 404-412.
  9. Henricson K, Hanson BS, Melander A, Ramethsteiner G, Ranstam J, Stenberg P. Socioeconomic factors, disease and drug utilisation. Pharmacoepid Drug Safety 1998; 7: 261-267.
  10. Olsson J, Lindberg G, Sjöstrand Å, Lindwall K, Råstam L, Melander A. Glycaemic control in NIDDM patients and its relation to inpatient care utilisation, short-term sick leave and premature retirement. Diab Nutr Metab 1998; 11: 232-236.
  11. Henricson K, Melander E, Mölstad S, Ranstam J, Hanson B S, Ramethsteiner G, Stenberg P, Melander A. Intraurban variation of antibiotics utilisation in children: Influence of socioeconomic factors. Eur J Clin Pharmacol 1998; 54: 653-657.
  12. Carlsson R. Serum cholesterol, lifestyle, working capacity and quality of life in patients with coronary heart disease. Experiences from a hospital-based secondary prevention programme. Scand Cardiovasc J 1998; 32 (Suppl 50). Doctoral Dissertation, Lund University.
  13. Christesen HBT, Melander A. Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. Eur J Endocrinol. 1998;138:698-701.

  14. Lindberg G. Läkemedelsbehandling av hypertoni i primärvården. Terapival och dess kostnader. NEPI-Rapport 1998 ISBN 91-8627-477-5. (Pharmacological treatment of hypertension in primary health care). Länk till sammanfattning av NEPI-rapport
  15. Lindberg G, Hallas J. Cholesterol-lowering drugs and antidepressants - a study of prescription symmetry. Pharmacoepid Drug Safety 1998;7:399-402.

  16. Melander A, Lindberg G, Olsson J, Ranstam J, Rastam L. Increased mortality in NIDDM patients on antihypertensive treatment with calcium channel blockersDiabetologia 1998;41:(Suppl 1) 1357A (meeting abstract).

1999

  1. Merlo J, Lindberg G, Lindblad U, Lindgren A, Råstam L, Melander A. Utilization of cardiovascular drugs (blood pressure lowering drugs, lipid lowering drugs and nitrates) and mortality from ischaemic heart disease and stroke. Eur J Clin Pharmacol 1999;55:69-76.
  2. Henricson K, Ramethsteiner G, Stenberg P, Melander A. Utilisation of codeine and d-propoxyphene: geographic and demographic variations in prescribing, prescriber and recipient categories. Eur J Clin Pharmacol 1999;55:605-611.
  3. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Rusell PT, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649-52.
  4. Lindberg G, Råstam L, Nilsson-Ehle P, Lundblad A, Ranstam J, Folsom AR, Burke GL. Serum sialic acid and sialoglycoproteins in asymptomatic carotid artery atherosclerosis. Atherosclerosis 1999;146:65-69.
  5. Hermann LS. Ranstam J, Vaaler S, Melander A. Effects of antihyperglycaemic theapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. Diabetes Obes Metab 1999;1:227-32.
  6. Östgren CJ, Lindblad U, Boegh-Hansen E, Ranstam J, Melander A, Råstam L. Differences in treatment and metabolic abnormalities between normo- and hypertensive NIDDM patients Diabetes Obes Metab 1999;1:105-112.
  7. Westerlund T, Almarsdóttir AB, Melander A: Drug related problems and pharmacy interventions in community practice. Int J Pharmacy Pract 1999;7:40-50.
  8. Vaaler S, Melander A. Perorale antidiabetika. Diabeteshåndboken, 2 uppl (ISBN 82-00-42971-7), Universitetsforlaget AS 1999, pp 102-106.
  9. Mölstad S, Cars O. Major change in the use of antibiotics following a national programme: Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance (STRAMA). Scand J Infect Dis 1999;31:191-195.

  10. Melander A, Nilsson E, Nilsson L, Liedholm H, Lindahl S-O, Lindblad U. Onödigt dyra läkemedel vid hypertoni: Spara 300 miljoner kronor per år med oförändrad medicinsk effektivitet. NEPI-rapport 1999.Länk till sammanfattning av NEPI-rapport
  11. Lindberg G, Lindblad U, Melander A. Patientnytta och patientrisker vid blodtrycksbehandling med kalciumantagonister - En litteraturöversikt. NEPI-rapport 1999.
  12. Melander A, Olsson J, Lindberg G. Increased mortality in type 2 diabetes patients using sulphonylurea and metformin in combination. Diabetologia 1999;42;1 (meeting abstract).
  13. Liedholm H, Linne AB, Merlo J. Pharmacological treatment of systolic heart failure. Lancet 1999;345:1471 (letter).
  14. Melander A, Lindblad U, Ranstam J. The NEPI antidiabetes study (NANSY), a Scandinavian complement to the DPP study. Diabetes 1999;48:(Suppl. 1) A351 (meeting abstract).
  15. Jönsson A, Hallengren B, Rydberg T, Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetologia 1999;42:916 (meeting abstract).
  16. Melander A, Nilsson JLG. Styrande läkemedelskostnader: Kostnadsmedveten läkemedelsanvändning. NEPI-rapport 1999.
  17. Westerlund T, Almarsdottír A B, Melander A. Factors influencing the detection rate of drug-related problems in community pharmacy. Pharm World Sci 1999;21:245-250.
  18. Bengtsson K, Orho-Melander M, Lindblad U, Melander O, Bog-Hansen E, Ranstam J, Rastam L, Groop L Polymorphism in the angiotensin converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg Hypertension and diabetes project. J Hypertens 1999;11:1569-1575.

2000


  1. Bille H, Lithman T, Luthman C, Melander A, Merlo J, Nissen A, Noreen D. Forbrug av Läkemedel i Skåne og Østdanmark. Rapport 2000.Läs bakgrundsbeskrivning.


  2. Nilsson JLG. Förbättrad läkemedelsanvändning genom bättre följsamhet till läkemedelsordinationen.Förslag till gemensamma mål för läkare, sjuksköterskor och farmaceuter.Rapport i samverkan mellan Landstingsförbundet, Kommunförbundet, Svensk Sjuksköterskeförening, Apotekarsocieteten, NEPI, Svenska Läkaresällskapet och Apoteket AB
  3. Nordling S, Lindberg G, Sandberg C, Anell A, Melander A, Rydberg T. Hur gick försöket med generisk substitution i Skåne? Rapport från IHE, NEPI och Apoteken i Skåne.
  4. Hagquist C, Silburn SR, Zubrick SR, Lindberg G, Ringbäck Weitoft G. Suicide and mental health problems among Swedish youth in the wake of the 1990s recession. Social Welfare 2000;3:211-219.
  5. Andrew JK, Clifford JB, Melander A. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. Br Med J 2000;321:252-253 (editorial).
  6. Merlo J, Lindberg G, Ranstam J, Östergren PO, Melander A, Råstam L. Systolic Blood Pressure and Mortality. A 20-Year Survival Analysis in a Cohort of 31,584 Individuals. Circulation 2000;102(supplement II):II854. Meeting abstract.
  7. Merlo J, Östergren PO, Månsson NO, Hanson BS, Ranstam J, Blennow G, Isacsson S-O, Melander A. Mortality in elderly men with low psychosocial coping resources using anxiolytics-hypnotics drugs. Scand J Public Health 2000;4;294-7.
  8. Nilsson JLG, Melander A. Use of generic drugs and effects of the reference price system in Sweden. Drug Info J 2000;34:1195-1200.
  9. Hermann LS. Optimising Therapy for Insulin-Treated Type 2 Diabetes Mellitus. Drugs Aging 2000;4:283-94
  10. Nilsson JLG, Andersson Å, Kälvemark S, Lieberman-Ram H, Ullenius B, Wendel A, Åberg Å. Surveys of drug-related therapy problems of patients using medicines for allergy, asthma and pain. Int J Pharm Pract 2000;8:198-203.
  11. Merlo J, Berglund G, Wirfält E, Gullberg B, Hedblad B, Manjer J, Hovelius B, Janzon L, Hanson BS, Östergren PO. Self-administered questionnaire compared with a personal diary for assessment of current use of hormone therapy: an analysis of 16,060 women. Am J Epidemiol 2000;152:788-792.
  12. Östgren CJ, Lindblad U, Ranstam J, Melander A, Rastam L. Associations between smoking and beta-cell function in a non-hypertensive and non-diabetic population. Skaraborg Hypertension and Diabetes Project. Diabet Med 2000;6:445-450.
  13. Nordling S, Lindberg G, Sandberg C, Anell A, Melander A, Rydberg T. Hur gick försöket med generisk substitution i Skåne?. Rapport från NEPI m fl., 2000.
  14. Lindberg G, Olsson J, Melander A. Use of calcium channel blockers and beta blockers as antihypertensives in relation to mortality in type 2 diabetes patients. A population based observational study. Pharmacoepid Drug Safety 2000;9:127-31.
  15. Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand Å, Tisell A, Melander A. Increased mortality in type 2 diabetes patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000;43:558-560.
  16. Jönsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JA, Melander A. Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol 2000;55:721-7.
  17. Jönsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JA, Melander A. Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol 2000;56:711-4.

2001

  1. Merlo J, Östergren P-O, Broms K, Björk-Linné A, Liedholm L. Survival after initial hospitalisation for heart failure: a multilevel analysis of patients in Swedish acute care hospitals. J Epidemiol Community Health 2001;55:323-329.
  2. Lindberg G, Lindblad U, Low-Larsen B, Merlo J, Melander A, Råstam L. Calcium channel blockers and prognosis. An observational study of mortality and cancer incidence in hypertensive patients. Meeting abstract presented at the American Heart Association 41st Annual Conference on Cardiovascular Disease Epidemiology and Prevention February 28- March 3, 2001, San Antonio, TX. Circulation 2001;103:1360-e.
  3. Andersson S, Troein M, Lindberg G. Conceptions of depressive disorder and its treatment among 17 Swedish general practitioners. A qualitative interview study. Family Practice 2001;18:64-70. 
  4. Merlo J, Liedholm H, Lindblad U, Björck-Linné A, Fält J, Lindberg G, Melander A. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ 2001;323:428-8.
  5. Merlo J, Broms K, Lindblad U, Björck-Linné A, Liedholm H, Östergren PO, Erhardt L, Råstam R, Melander A. Association of outpatient utilisation of non-steroidal anti-inflammatory drugs and hospitalised heart failure in the entire Swedish population. Eur J Clin Pharmacol. 2001;57:71-5
  6. Nilsson JLG, Melander A. Jämförpriser på läkemedel. Läkemedelpriser/kostnader i kronor per dygnsdos under år 2000. Ett hjälpmedel för att bedöma kostnadseffekten av preparatrekommendationer. NEPI-rapport 2001.
  7. Nilsson JLG, Melander A. Läkares relationer till läkemedelskommittéer. Attityder och faktisk förskrivning. NEPI-rapport 2001.
  8. Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357:1851-3.
  9. Håkansson A, Andersson H, Cars H, Melander A. Prescribing, prescription costs and adherence to formulary committee recommendations: long-term differences between physicians in public and private care. Eur J Clin Pharmacol. 2001;57:65-70.
  10. Matsson L, Twetman S, Nilsson JLG, Melander A. Trender i försäljning av olika fluorpreparat 1988-1999. Tandläkartidningen 2001;93(8):34-8.
  11. Lindberg G, Merlo J, Råstam L, Melander A. Cause Specific Mortality at the Lower Extreme of Serum Cholesterol Distribution. A Population Based Study. Abstract presented at the American Heart Association Scientific Sessions 2001, Anaheim, California, November 11-14. Circulation 2001;104:II-810.
  12. Lindberg G, Lindblad U, Low-Larsen B, Merlo J, Melander A, Råstam L. Use of Calcium Channel Blockers as Antihypertensives in Relation to Mortality and Cancer Incidence. A Population Based Observational Study. Abstract presented at the 4th International Congress on Coronary Heart Disease from Prevention to Intervention, Prague, October 21-24, 2001.
  13. Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand Å, Tisell A, Melander A. Differences in pharmacotherapy and in glucose control of type 2 diabetes patients in two neighbour towns: A longitudinal population-based study. Diabetes, Obesity & Metabolism 2001;3:259-253.
  14. Merlo J, Östergren PO, Hagberg O, Lindström M, Lindgren A, Melander A, Råstam L, Berglund G. Diastolic blood pressure and area of residence: multilevel versus ecological analysis of social inequity. J Epidemiol Community Health 2001;55;791-798.
  15. Rapport från Arbetsgruppen för bättre läkemedelsanvändning (ABLA II) Mindre sjukdom och bättre hälsa genom ökad följsamhet till läkemedelsordinationerna - Professionernas roll
  16. Andersson S, Lindberg G, Troein M. Hur formas allmänläkares sätt att arbeta med depressiva patienter? En kvalitativ intervjustudie. Abstract vid Svenska Läkarsällskapets Riksstämma 28-30 nov 2001

  17. Merlo J, Lithman D, Noreen D, Melander A. Läkemedelsanvändare i Skåne 2000. Rapport i samverkan med Läkemedelsrådet i Skåne och Samhällsmedicinska Institutionen, Lunds Universitet (Malmö) Länk till hela rapporten i pdf-format 

  18. Merlo J, Lithman D, Noreen D, Melander A. Läkemedelsanvändares utnyttjande av sjukvård - en studie i Skåne. Rapport i samverkan med Läkemedelsrådet i Skåne och Samhällsmedicinska Institutionen, Lunds Universitet (Malmö) Länk till hela rapporten i pdf-format
  19. Jönsson A, Hallengren B, Rydberg T, Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 2001;3:403-9.
  20. Hermann LS, Kalén J, Katzman P, Lager I, Nilsson A, Norrhamn O, Sartor G, Ugander L. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 2001;3:428-34.
  21. Lindblad U, Lindwall K, Sjöstrand Å, Ranstam J, Melander A. The NEPI Antidiabetes Study (NANSY): 1. Short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabetes Obes Metab 2001;3:443-51.
  22. Läkemedelsanvändares utnyttjande av sjukvård - en studie i Skåne.  Rapport i samverkan med Läkemedelsrådet i Skåne och Samhällsmedicinska Institutionen, Lunds Universitet (Malmö)
  23. Läkemedelsanvändare i Skåne 2000. Rapport i samverkan med Läkemedelsrådet i Skåne och Samhällsmedicinska Institutionen, Lunds Universitet (Malmö)

2002

  1. Bensodiazepiner och deras analoger: Användning – Beroende – Styrfaktorer. NEPI-Rapport i samverkan med Läkemedelskommittén i Jönköpings läns landsting och Läkemedelsrådet i Skåne
  2. Merlo J, Liedholm H, Lindblad, Fält J, Lindberg G, Melander. Bättre läkemedelsbehandling kan gynna folkhälsan en studie av möjliga läkemedelsinteraktioner i apoteksexpedieringar. Läkartidningen 2002:99:922-5.
  3. Andersson SJ, Lindberg G, Troein M. What shapes GPs’ work with depressed patients? A qualitative interview study. Family Practice 2002;19:623-31. 
  4. Bronzwaer SL, Cars O, Buchholz U, Mörstad S, Goettsch W, Veldhuijzen IK, Kool JL, Sprenger MJW, Degener JE, EARSS participants. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis. 2002;8:278-82.
  5. Lindberg G, Lindblad U, Löw-Larsen B, Merlo J, Melander A, Råstam L. Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence. A population based observational study.Pharmacoepid Drug Safety 2002;11:493-7.
  6. Kurt Boman Jan-Erik Ögren. Utsättning av läkemedel - kliniskt viktigt men praktiskt svårt. NEPI-rapport 2002 (ISBN 91-9743-181-X)
  7. Boeg-Hansen E, Lindblad U, Ranstam J, Melander A, Råstam L. Antihypertensive drug treatment in a Swedish community: Skaraborg Hypertension and Diabetes Project. Pharmacoepidemiol Drug Saf 2002;:45-54
  8. Arne Melander, Gunnar Lindberg, Juan Merlo, Thomas Kjellström, J Lars G Nilsson. Statiner: Effekter - Patientnytta - Användning - Vinster - Kostnader. NEPI-rapport 2002 (ISBN 91-9743-181-8).
  9. Hermann L, Lindberg G, Lindblad U, Melander A. Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes. Diabetes Obes Metab 2002;5:296-304
  10. Ekedahl A, Wessling A, Melander A. Primacy non-compliance with automated prescription transmittals from health care centres in Sweden. Journal of Social and Administrative Pharmacy 2002;19:137-40.
  11. Östgren CJ, Lindblad U, Melander A, Råstam L. Survival in patients with type 2 diabetes in a Swedish community: Skaraborg hypertension and diabetes project. Diabetes Care 2002;25:1297-302.

2003

  1. Gustafsson J, Kälvemark S, Nilsson G, Nilsson JLG. A Method to Evaluate Patient Information Leaflets. Drug Information Journal 2003;37:115-25.
  2. Nilsson SE, Johansson B, Takkinen S, Berg S, Zarit S, McClearn G, Melander A. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged >80 years. Eur. J. Clin. Pharmacol. 2003;59:313-9.
  3. Andersson ÅC, Brodin H, Nilsson JLG. Pharmacists interventions in relations to patient drug-related problems. JSAP 2003;20:82-91.
  4. Bög-Hansen E, Lindblad U, Gullberg B, Melander A, Råstam L. Metabolic disorders associated with uncontrolled hypertension - Skaraborg hypertension and diabetes project. Diabetes, Obesity & Metabolism  2003;4:379-387.
  5. Melander A, Zawadzki AM, Liu Q, Wang YS, Jeppsson B, Thorlacius H. Antihypertensive calcium channel blockers may promote human cancer cell growth. Am J Hypertension 2003;16:OR24 Part 2.
  6. Östgren CJ, Lindblad U, Melander O, Melander A, Groop L, Råstam L. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J Hypertension 2003;21:1657-1662.
  7. Melander E, Nissen A, Henricson K, Merlo J, Molstad S, Kampmann JP, Lithman T, Hansen EH, Melander A. Utilisation of antibiotics in young children: opposite relationships to adult educational levels in Danish and Swedish counties. Eur J Clin Pharmacol 2003;59:331-335.

2004

  1. Nilsson SE, Takkinen S, Johansson B, Dotevall G, Melander A, Berg S, McClearn G. Laxative treatment elevates plasma homocysteine: a study on a population-based Swedish sample of old people. Eur J Clin Pharmacol 2004;60:45-49.
  2. Arne Melander, J Lars G Nilsson. Marknadsföring av läkemedel: Effekter på behandlingens inriktning och kostnader. NEPI-rapport 2004.
  3. Melander A, Nilsson JLG. Pricing and Costs of Drugs in the United States and Sweden: A Comparison Based on Drug Acquisition Costs at the Patient Outcome Level. Journal of Ambulatory Care Management 2004;27:115-119.
  4. Merlo J, Asplund K, Lynch J, Råstam L, Dobson A. Population Effects on Individual Systolic Blood Pressure: A Multilevel Analysis of the World Health Organization MONICA Project. Am J Epidemiol. 2004;159:1168-1179.
  5. Gunnar Lindberg, Arne Melander. Kan läkemedel förebygga ohälsa?  NEPI-rapport 2004;(ISBN 91-9743-186-9).

2005

  1. Andersson SJ, Lindberg G, Troein M. General practitioners' conceptions of depressive disorders in relation to regional sales levels of antidepressive drugs. SJPHC 2005;23:11-17.
  2. Andersson SJ, Troein M,.Lindberg G. General practitioners' conceptions about treatment of depression and factors that may influence their practice in this area. A postal survey. BMC Family Practice 2005, 6:21.
  3. Ekedahl A, Lindberg G. Differences Between Drug Utilisation Estimates Based on Pharmacy Sales and on Purchases by the Resident Population. Pharm World Sci 2005;27:469-71.
  4. Ohlsson H, Lindblad U, Lithman T, Ericsson B, Gerdtham U-G, Melander A, Råstam L, Merlo J. Understanding adherence to official guidelines on statin prescribing in primary health care—a multi-level methodological approach. Eur J Clin Pharmacol 2005 (online first). 

2006

  1. Johnell K, Månsson N-O, Sundquist J, Melander A, Blennow G, Merlo J. Neighborhood social participation, use of anxiolytic-hypnotic drugs, and women’s propensity for disability pension: a multilevel analysis. Scandinavian Journal of Public Health 2006;34:41-48.
  2. Nilsson JLG, Lindberg G, Johansson H, Melander A. Correlation of drug utilisation and morbidity at the municipality level. High use of antibiotics associated with low use of antihypertensives. Eur J Clin Pharmacol 2006;62:675-680.
  3. Nilsson JLG, Andersson K, Bergkvist A, Björkman I, Brismar A, Moen J. Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care 2006;15:235-7.
  4. Melander A, Folino-Gallo P, Walley T, Schwabe U, Groop PH, Klaukka T, Vallano A, Laporte JR, Gallego MR, Schiappa M, Roder M, Kampmann JP, de Swaef A, Aberg M, Mansson NO, Lindblad U. Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia 2006;49: 2024-9.
  5. Nilsson, JLG, Melander A. Increased introduction, advertising and sales of preventive drugs 1986-2002 in Sweden. J Ambul Care Management 2006;29:238-49.
  6. Krigsman K, Nilsson JLG and Ring L. Refill adherence for patients with asthma and COPD: comparison of a pharmacy record data base with collected repeat prescriptions. Pharmacoepidemiol Drug Saf. 2006 Sep 28; [Epub ahead of print]
  7. Haupt D, Nilsson JLG The role of prescribed and defined daily doses and pharmacoepidemiology WHO Drug Inform 2006;20:261-4.

2007

  1. Lindberg G. Resialylation of sialic acid deficit vascular endothelium, circulating cells and macromolecules may counteract the development of atherosclerosis: A hypothesis. Atherosclerosis. 2007;192,:243-245.
  2. Nilsson SE, Read S, Berg S, Johansson B, Melander A, Lindblad U. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007 Feb;19(1):41-7.
  3. Nilsson JLG, Bäckström S, Sundström J. Electronically transferred prescriptions: picked up faster than paper prescriptions. Int J Pharm Pract 2007;15:157-158.
  4. Krigsman K, Nilsson JLG and Ring L. Adherence to multiple drug therapies: Refill adherence to concomitant use of diabetes and asthma/COPD medication. Pharmacoepidemiol Drug Saf 2007 June 13; [Epub ahead of print].
  5. Melander A, Lindberg G, Nilsson JLG. Can drug treatment prevent disease in common practice? Zeitschrift für ärztliche Fortbildung und Qualität im Gesundheitswesen 2007;101:326-32.
  6. Tyrberg M, Melander A, Lövestam-Adrian M, Lindblad U. Retinopathy in subjects with impaired fasting glucose: the NANSY-Eye baseline report. Diabetes Obes Metab. 2007 Jul 21; [Epub ahead of print]

 

 

tablett